What’s Going On With Pfizer Stock Today?
Pfizer to announce Q4 2023 earnings on 30th Jan. Analysts project EPS loss of $(0.22) and $14.25B in revenues.
Abbott Received Approval From FDA To Launch The Liberta RC DBS System With Remote Programming Capabilities to Treat Movement Disorders
Liberta RC™ deep brain stimulation (DBS) system, recently approved by the U.S. FDA, features NeuroSphere™ Virtual Clinic, which allows for remote programming of the systemSystem offers the longest time
SELLAS Life Sciences To Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients At The 2024 European School Of Haematology Conference
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today
Concord Acquisition Corp III Receives Noncompliance Notification from the New York Stock Exchange Regarding Minimum Public Stockholders
Concord Acquisition Corp III (the "Company") announced it had received a notification dated January 19, 2024 (the "Notice") from the New York Stock Exchange (the "NYSE") informing the Company that, because the number of
Scholar Rock Announces Presentation Of New Preclinical Data Evaluating SRK-439 In Obesity At Keystone Symposia
SRK-439 is a novel selective myostatin inhibitor designed for the treatment of cardiometabolic disordersPreclinical data supports the potential of SRK-439 to preserve lean muscle mass as part of healthy weight
Exelixis Announces Detailed Results Of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib In Combination With Atezolizumab In Metastatic Castration-Resistant Prostate Cancer Presented At ASCO GU 2024
– Cabozantinib in combination with atezolizumab reduced the risk of disease progression or death by 35% in patients with metastatic castration-resistant prostate cancer –– Findings to be presented during an oral
Ensysce Biosciences To Present Groundbreaking Oral Overdose Protection For Opioids At The 5th Annual NIH HEAL Meeting
Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced
Incannex Commences Dosing In Phase 2 Clinical Trial Assessing IHL-675A In Patients With Rheumatoid Arthritis
Incannex Healthcare Inc. (NASDAQ:IXHL), (‘Incannex' or the ‘Company'), a pharmaceutical company developing novel medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies for unmet medical needs, is
ClearPoint Neuro Announces Installation And First Procedure Using The ClearPoint Prism Neuro Laser Therapy System And Navigation System At Kaleida Health In Buffalo
ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced installation and completion of an initial
Slow Market Penetration For Biogen’s Another Alzheimer’s Drug: UBS Highlights Risks, Forecasts
UBS insights on Biogen Inc's challenges with Leqembi in the Alzheimer's market. Analyst downgrades, revised sales estimates, and CEO's growth strategy.